Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The NTCI cSN50.1 peptide currently in clinical trials specifically demonstrated itch reduction
Injury location: Well-vascularized areas like muscles heal faster than poorly vascularized tendons or ligaments
Importantly for MCS, the two receptors modulate and sensitize each other
These molecular interactions facilitate activation of the Ras/RAF/MEK/ERK pathway, quantifiable through phospho-specific antibody detection and real-time PCR analysis of immediate early gene expression profiles
US$ 26.56
US$ 20.39
US$ 28.70
US$ 26.23
US$ 23.63
US$ 28.83
US$ 23.31
